XML 72 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Certain Transactions - Other Transactions - Additional Information (Detail) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 26, 2023
Nov. 09, 2023
Jun. 12, 2023
May 12, 2017
Oct. 31, 2021
Aug. 31, 2021
Dec. 31, 2016
Dec. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2023
Oct. 03, 2023
Sanofi [Member] | Collaborative Arrangement [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Upfront payment                           $ 500  
Milestone payment receivable                             $ 500
Development and launch milestone payment receivable                             $ 1,000
Johnson And Johnson [Member] | Settlement And License Agreement Alvotech And Teva [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Maximum entry date for granting license entry     Feb. 21, 2025                        
Biolojic Design Ltd [Member] | Collaborative Arrangement [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Additional development and milestone payments receivable               $ 500           500  
Biolojic Design Ltd [Member] | Research and Development Expense [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Milestone payment $ 10                            
Royalty Pharma [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Collaborative agreement milestone payments   $ 100                          
Collaborative agreement milestone amount increase   $ 125                          
Royalty Pharma [Member] | Research and Development Expense [Member] | Collaborative Arrangement [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Reimbursement of research and development expenses incurred               $ 35              
Otsuka [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Upfront payment       $ 50                      
Milestone payment                       $ 35 $ 15    
Takeda [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Upfront payment             $ 30                
Milestone payment             20     $ 25          
Collaborative agreement milestone payments             $ 519                
Alvotech [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Collaborative agreement milestone payments                           $ 400  
MedinCell [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Milestone payment                 $ 3            
Collaborative agreement milestone payments           $ 105                  
MODAG [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
License agreement potential aggregate milestone payments amount         $ 30                    
MODAG [Member] | Research and Development Expense [Member]                              
Noncash or Part Noncash Acquisitions [Line Items]                              
Milestone payment                     $ 10